Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real‐world study

Lymphoid neoplasms treatment has recently been renewed to increase antitumor efficacy and conventional chemotherapies toxicities. Limited data have been published about the infection risk associated with these new drugs, therefore this study analyzes the infectious complications in patients with lymphoproliferative diseases (LPD) treated with monoclonal antibodies (obinutuzumab, ofatumumab, brentuximab, nivolumab, or pembrolizumab), BTK inhibitors (ibrutinib and acalabrutinib), PI3K inhibitors (idelalisib) and BCL2 inhibitors (venetoclax).

[1]  M. Slavin,et al.  Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns , 2020, Leukemia & lymphoma.

[2]  L. Pagano,et al.  Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study , 2020, Leukemia & lymphoma.

[3]  F. Salvo,et al.  Patterns of use and safety of ibrutinib in real‐life practice , 2020, British journal of clinical pharmacology.

[4]  A. Wiestner,et al.  Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors , 2020, Leukemia & lymphoma.

[5]  I. Ruiz-Camps,et al.  Risk of infection associated with new therapies for lymphoproliferative syndromes , 2020 .

[6]  T. MaCurdy,et al.  Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries. , 2019, JAMA oncology.

[7]  M. Luppi,et al.  Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. , 2019, Blood reviews.

[8]  J. Woyach,et al.  Targeting BTK in CLL: Beyond Ibrutinib , 2019, Current Hematologic Malignancy Reports.

[9]  J. Byrd,et al.  Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies , 2019, Leukemia.

[10]  T. Franquet,et al.  Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) , 2019, Leukemia.

[11]  R. Advani,et al.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial , 2019, The Lancet.

[12]  J. Gea-Banacloche,et al.  Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. , 2018, Blood reviews.

[13]  G. Redelman-Sidi,et al.  Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  G. Ippolito,et al.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  A. Wiestner,et al.  Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia , 2018, Leukemia & lymphoma.

[16]  M. Davids,et al.  Risk of hepatitis B virus reactivation in patients treated with ibrutinib. , 2018, Blood.

[17]  M. Janelsins,et al.  Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies , 2018, Leukemia & lymphoma.

[18]  R. Le Calloch,et al.  Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia? , 2018, Medecine et maladies infectieuses.

[19]  O. Bairey,et al.  Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival , 2018, Hematological oncology.

[20]  D. Kontoyiannis,et al.  Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  G. Salles,et al.  Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC‐based first‐line treatment: Retrospective observations from the FILO group , 2018, American journal of hematology.

[22]  Michael L. Wang,et al.  Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[23]  J. Connors,et al.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma , 2017, The New England journal of medicine.

[24]  L. Trentin,et al.  Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia , 2017, Hematological oncology.

[25]  W. Klapper,et al.  Obinutuzumab for the First‐Line Treatment of Follicular Lymphoma , 2017, The New England journal of medicine.

[26]  T. Shanafelt,et al.  Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors , 2017, Leukemia & lymphoma.

[27]  C. Grommes,et al.  Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. , 2017, Cancer cell.

[28]  A. Alanio,et al.  Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis , 2017, Leukemia & lymphoma.

[29]  G. Salles,et al.  Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study , 2017, Haematologica.

[30]  B. Arthurs,et al.  Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia , 2017, Respiratory medicine case reports.

[31]  L. Pagano,et al.  Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. , 2017, Blood reviews.

[32]  F. D'Alo',et al.  Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study , 2017, Haematologica.

[33]  T. Kipps,et al.  Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. , 2017, The Lancet. Oncology.

[34]  K. Savage,et al.  Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study , 2016, The Lancet. Oncology.

[35]  K. Savage,et al.  Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study , 2016, The Lancet. Oncology.

[36]  W. Klapper,et al.  First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. , 2016, The Lancet. Oncology.

[37]  G. Gordon,et al.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. , 2016, The Lancet. Oncology.

[38]  Mingzhi Zhang,et al.  Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor , 2016, Journal of Hematology & Oncology.

[39]  G. Marti,et al.  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. , 2015, Blood.

[40]  T. Ebert,et al.  Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia , 2015, Annals of Hematology.

[41]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[42]  R. Ulrich,et al.  Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. , 2014, Blood.

[43]  M. Keating,et al.  Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia , 2013, Cancer.

[44]  Jeffrey A Jones,et al.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. , 2013, Blood.

[45]  Jeffrey A Jones,et al.  Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals , 2010 .

[46]  R. Chemaly,et al.  Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention , 2010, Bone Marrow Transplantation.

[47]  S. Molica.  Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. , 1994, Leukemia & lymphoma.

[48]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[49]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.